US · BRTX
BioRestorative Therapies, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Melville, NY 11747
- Website
- biorestorative.com
Price · as of 2024-12-31
$0.23
Market cap 2.03M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $43.16 | +18,399.79% |
| Intrinsic Value(DCF) | $3.02 | +1,194.47% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $120,000.00 | ||||
| 2013 | $51,200.00 | $800,075.90 | $0.00 | $0.00 | $1,865,303.22 |
| 2014 | $35,200.00 | $31,504.13 | $2,789,122.10 | $0.00 | $0.00 |
| 2015 | $17,400.00 | $54,151.41 | $240,660,568.74 | $0.00 | $0.00 |
| 2016 | $17,200.00 | $23,879.18 | $64,512.49 | $0.00 | $603,024.40 |
| 2017 | $13,480.00 | $177,184.00 | $21,744,629.25 | $0.00 | $0.00 |
| 2018 | $2,654.40 | $7,170.16 | $3,849,618.78 | $0.00 | $0.00 |
| 2019 | $1.20 | $1,608.08 | $2,057,037.53 | $0.00 | $0.00 |
| 2020 | $52.00 | $2,240.24 | $38.83 | $0.00 | $882.38 |
| 2021 | $4.20 | $82.94 | $34.13 | $0.00 | $1,131.02 |
| 2022 | $3.02 | $78.87 | $1.45 | $0.00 | $0.00 |
| 2023 | $1.31 | $18.41 | $3.69 | $0.00 | $0.00 |
| 2024 | $1.55 | $43.16 | $65,758.63 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates BioRestorative Therapies, Inc.'s (BRTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $43.16
- Current price
- $0.23
- AI upside
- +18,399.79%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.02
+1,194.47% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BRTX | BioRestorative Therapies,… | $0.23 | 2.03M | +18,400% | +1,194% | — | — | -1.34 | 1.41 | 30.01 | -0.11 | — | 1.52 | 93.00% | -2881.59% | -2239.25% | -96.89% | 745.38% | -72.15% | 0.00 | — | 2.97 | 2.91 | 0.05 | -5304.00% | 17503.00% | 2629.00% | -69.27% | -2.20 | 537.75% | 0.00% | 0.00% | 0.00% | -0.11 | -0.16 | 3.25 | -18.17 |
| BOLT | Bolt Biotherapeutics, Inc… | $4.52 | 8.68M | +449% | -22% | — | — | -5.28 | 5.82 | 43.30 | -4.68 | — | 5.82 | 100.00% | -949.91% | -820.78% | -74.28% | -221.84% | -48.66% | 0.44 | — | 3.20 | 3.06 | -0.27 | -984.00% | -236.00% | -1205.00% | -18.42% | -3.87 | -186.26% | 0.00% | 0.00% | 0.00% | -4.26 | -5.07 | 40.42 | -3.22 |
| COCP | Cocrystal Pharma, Inc. | $1.05 | 10.76M | — | — | — | — | -0.99 | 1.82 | — | -0.52 | 0.00 | 1.82 | 0.00% | — | — | -97.50% | -1066.39% | -78.29% | 0.19 | — | 4.77 | 4.56 | 0.45 | 9042632.00% | — | 1156.00% | -95.36% | -6.79 | -983.78% | 0.00% | 0.00% | 0.00% | -0.52 | -0.56 | — | -35.62 |
| DWTX | Dogwood Therapeutics, Inc… | $2.85 | 5.45M | — | — | — | — | -0.55 | 0.11 | — | -0.61 | -0.71 | -0.51 | 0.00% | — | — | -36.28% | -37.33% | -25.08% | 0.24 | -132.63 | 5.21 | 4.67 | -0.06 | 7759.00% | — | 8049.00% | -129.59% | -2.77 | -26.84% | 0.00% | 0.00% | 0.01% | -0.62 | -0.86 | — | -1.22 |
| EDSA | Edesa Biotech, Inc. | $2.20 | 18.37M | — | — | — | — | -1.39 | 0.80 | — | 0.11 | — | 0.95 | 0.00% | — | — | -99.57% | -603.13% | -82.86% | 0.00 | — | 10.67 | 10.60 | 1.53 | -3420.00% | — | 4973.00% | -73.29% | -6.79 | -558.20% | 0.00% | 0.00% | 97.84% | 0.10 | 0.11 | — | -2.27 |
| EVGN | Evogene Ltd. | $0.88 | 7.65M | +2,548% | -33% | — | — | -0.47 | -5.81 | 0.99 | -0.39 | — | -0.62 | 39.81% | -255.36% | -193.69% | -340.58% | 381.57% | -39.69% | -8.87 | -175.27 | 1.15 | 0.90 | 0.16 | -4474.00% | 5090.00% | -910.00% | -241.06% | -1.05 | 356.85% | 0.00% | 0.00% | 0.00% | -0.28 | -0.29 | 0.70 | -10.92 |
| IMNN | Imunon, Inc. | $3.25 | 8.19M | — | — | — | — | -0.56 | 2.47 | — | -0.32 | — | 2.47 | 0.00% | — | — | -211.21% | 3263.61% | -117.72% | 0.27 | — | 1.67 | 1.23 | 0.26 | -2500.00% | — | -303.00% | -180.33% | -3.94 | 3221.31% | 0.00% | 0.00% | 4.96% | -0.30 | -0.30 | — | -63.56 |
| IMRN | Immuron Limited | $0.77 | 4.96M | +2,352% | +18,330% | — | — | -3.14 | 2.04 | 2.25 | -2.00 | — | 2.04 | 65.39% | -73.34% | -71.58% | -50.30% | -304.73% | -40.68% | 0.01 | -731.63 | 5.07 | 3.39 | 0.51 | -2623.00% | 4863.00% | 436.00% | -37.47% | -3.12 | -349.90% | 0.00% | 0.00% | 0.00% | -1.99 | -1.73 | 1.46 | -6.75 |
| MRKR | Marker Therapeutics, Inc. | $1.48 | 15.98M | +3,230% | -2% | — | — | -1.26 | 0.73 | 2.04 | 0.51 | — | 0.73 | -104.33% | -168.69% | -162.82% | -65.81% | 1313.50% | -54.82% | 0.00 | — | 6.36 | 6.22 | 1.73 | -3834.00% | 9906.00% | -3364.00% | -81.00% | -3.15 | 1288.92% | 0.00% | 0.00% | 30.30% | 0.51 | 0.52 | -0.87 | -26.44 |
| SNSE | Sensei Biotherapeutics, I… | $30.50 | 38.48M | — | — | — | — | -7.50 | 5.89 | — | -6.39 | — | 5.89 | 0.00% | — | — | -58.40% | -1014.51% | -50.37% | 0.10 | -351.81 | 7.70 | 7.59 | 0.21 | -164.00% | — | -2294.00% | -10.98% | -4.53 | -795.13% | 0.00% | 0.00% | 0.00% | -5.96 | -7.60 | — | 10.02 |
| TRAW | Traws Pharma, Inc. | $1.65 | 7.87M | +1,216% | +24,103% | — | — | -0.08 | -0.14 | 19.44 | 0.10 | -0.14 | -0.14 | 94.69% | -21835.40% | -24192.04% | 521.75% | 156.37% | -229.51% | 0.00 | — | 2.16 | 2.00 | 0.13 | 5601.00% | 0.00% | 6601.00% | -678.00% | -2.58 | 94.40% | 0.00% | 0.00% | 11.77% | 0.34 | 0.57 | -74.97 | -42.23 |
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.
- CEO
- Lance Alstodt
- Employees
- 11
- Beta
- 0.24
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.02 ÷ $0.23) − 1 = +1,194.47% (DCF, example).